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Value of hospital antimicrobial stewardship
programs [ASPs]: a systematic review
Dilip Nathwani1, Della Varghese2, Jennifer Stephens2* , Wajeeha Ansari3, Stephan Martin2 and
Claudie Charbonneau4
Abstract
Background: Hospital antimicrobial stewardship programs (ASPs) aim to promote judicious use of antimicrobials
to combat antimicrobial resistance. For ASPs to be developed, adopted, and implemented, an economic value
assessment is essential. Few studies demonstrate the cost-effectiveness of ASPs. This systematic review aimed to
evaluate the economic and clinical impact of ASPs.
Methods: An update to the Dik et al. systematic review (2000–2014) was conducted on EMBASE and Medline
using PRISMA guidelines. The updated search was limited to primary research studies in English (30 September
2014–31 December 2017) that evaluated patient and/or economic outcomes after implementation of hospital
ASPs including length of stay (LOS), antimicrobial use, and total (including operational and implementation) costs.
Results: One hundred forty-six studies meeting inclusion criteria were included. The majority of these studies
were conducted within the last 5 years in North America (49%), Europe (25%), and Asia (14%), with few studies
conducted in Africa (3%), South America (3%), and Australia (3%). Most studies were conducted in hospitals with 500–
1000 beds and evaluated LOS and change in antibiotic expenditure, the majority of which showed a decrease in LOS
(85%) and antibiotic expenditure (92%). The mean cost-savings varied by hospital size and region after implementation
of ASPs. Average cost savings in US studies were $732 per patient (range: $2.50 to $2640), with similar trends
exhibited in European studies. The key driver of cost savings was from reduction in LOS. Savings were higher
among hospitals with comprehensive ASPs which included therapy review and antibiotic restrictions.
Conclusions: Our data indicates that hospital ASPs have significant value with beneficial clinical and economic
impacts. More robust published data is required in terms of implementation, LOS, and overall costs so that
decision-makers can make a stronger case for investing in ASPs, considering competing priorities. Such data
on ASPs in lower- and middle-income countries is limited and requires urgent attention.
Keywords: Antibiotic stewardship program, Antimicrobial resistance, Economic evaluation, Antimicrobial
stewardship
Background
Antimicrobial resistance (AMR) is a global problem
threatening not only public health but also economic
development and security. Globally, AMR has the po-
tential to cause 10 million deaths by 2050 based on
high-level scenarios [1]. The World Bank estimates that
there will be up to one trillion US dollars global in-
creases in healthcare costs by 2050 due to AMR [2].
AMR can stem from inappropriate antibiotic use which
can include overuse, misuse, underuse or abuse of antibi-
otics [3]. Rate of antimicrobial misuse in hospitals, includ-
ing failure to de-escalate and overprescription of broad
spectrum antibiotics, has remain unchanged at 50%. Anti-
microbial stewardship programs (ASPs) are one way to
address inappropriate antimicrobial use and AMR.
The goals of ASPs are to improve patient outcomes
and safety and to reduce AMR and healthcare costs by
promoting judicious use of antibiotics. Some core ele-
ments identified in successful ASPs include leadership
commitment, prescriber accountability, drug expertise
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and education of clinicians and patients, among others
[4, 5], ASPs may require additional resources, such as
hospital personnel and equipment, in order to be ef-
fective and be sustainable. As such, the upfront costs
associated with these additional resources can be a po-
tential barrier to individuals who have not yet imple-
mented an ASP. With the growing importance of
measuring the impact of ASPs and health economic
evaluations, there has been an increasing number of
studies that have evaluated the clinical and economic
impact of ASPs in the last few years.
A systematic review was conducted by Dik et al. to
evaluate methods of published economic evaluations of
hospital ASP studies from January 2000 to November
2014 [6]. The authors identified 99 studies, the majority
of which were conducted in North America and Europe.
Although distinct types of stewardship interventions
were evaluated, “Therapy evaluation, review and/or feed-
back” was the most common. As the primary objective
of this review was to evaluate only the quality of these
studies, no synthesis of results was performed or aggre-
gated results reported. Given the growing body of litera-
ture, an update of the Dik review including a complete
summary of the outcomes from these studies was still
needed. Therefore, our objective was to conduct a system-
atic review to update, evaluate, and broadly summarize
the clinical and economic impact of ASPs using the Dik
et al. framework.
Materials and methods
Literature search
This systematic review followed the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
protocol to synthesize the results related to key outcomes
from all the individual studies and define an overall value
framework for ASPs. The previously identified systematic lit-
erature review by Dik et al. (January 2000–November 2014)
was used to provide the framework for this review [6].
An updated search to the Dik et al. systematic review was
performed within the EMBASE and MEDLINE databases
to further include studies after 30 September 2014 up to 31
December 2017, using the following search strings: “anti-
microbial stewardship,” “antimicrobial management,” “anti-
microbial prescribing intervention,” and “antimicrobial
program intervention.” All strings were in combination
with the words “cost(s),” “financial,” “economic,” “dollar” or
“euro,” or the respective symbols for the latter two. Two au-
thors independently reviewed the retrieved abstracts for
their eligibility followed by full-text screening of selected ar-
ticles. Studies identified through a handsearching process
were also included.
Study selection
Primary research studies in English that discussed a hos-
pital intervention and key patient and/or economic out-
comes, identified previously by Dik et al., were included in
this analysis. Our review expanded the search to also
Fig. 1 PRISMA chart of the search method
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include studies published through December 2017 (Fig. 1).
Studies that did not contain an ASP intervention, measure
any key outcomes, or that were conducted in an animal
population were excluded. All inclusion and exclusion cri-
teria were established prior to the review.
Data extraction
Information collected from each study included publica-
tion year, region and country, study objective, study de-
sign, setting, hospital size (number of beds), number of
participants/patients included, inclusion and exclusion
criteria for study data. Information collected about the
intervention included type of intervention based on cat-
egories reported in Dik et al., description of the ASPs
(stewards and their role, components, duration, primary
outcomes), outcomes measured and their corresponding
results, and the conclusion of the study findings.
The main outcomes of interest were antimicrobial, patient
and economic outcomes. Antimicrobial outcomes included
antibiotic usage and resistance. Length of stay (LOS), mor-
tality rate, and readmission rates at varying timepoints were
the main patient outcomes of interest. Key economic out-
comes were costs associated with antimicrobials, LOS, and
Table 1 General characteristics of the reviewed studies
Characteristic Number Percentage
Geography (N = 146)
North America 72 49
South America 5 3
Europe 37 25
Asia 20 14
Africa 4 3
Middle East 3 2
Australia 4 3
Multi-Region 1 1
Publication Year (N = 146)
2000–2002 8 5
2003–2005 14 10
2006–2008 16 11
2009–2011 11 8
2012–2014 51 35
2015–2017 46 32
Study Design (N = 146)
ITS 16 11
Quasi-experimental study 77 53
Retrospective evaluation 11 8
RCT 14 10
Cost-analysis 10 7
Cross-sectional survey 2 1
Observational study 15 10
Unclear 1 1
Number of Beds in Hospital (N = 146)
< 150 13 9
150–500 28 19
500–1000 41 28
> 1000 26 18
Unclear 38 26
Number of Patients Included (N = 146)
< 100 12 8
100–250 20 14
250–500 17 12
500–1000 5 3
1000–1500 8 5
> 1500 21 14
Unclear 63 43
Abbreviations: ITS Interrupted time series, RCT Randomized controlled trials
Table 2 Types of interventions and outcomes
Number
of studies
Percentage
Intervention (N = 145)
Therapy evaluation, review and/or feedback 82 57
Altered therapy guidelines 37 25
Giving education 18 12
Antibiotic restriction lists of pre-authorization 15 10
Rapid diagnostic tools 11 8
New biomarkers 4 3
Pre-analytic consultations 2 1
Antibiotic cycling 1 1
Other 1 1
Outcome Measures (N = 146)
Antibiotic Use
Antimicrobial resistance 22 15
Antibiotic usage 100 68
Patient Outcomes
LOS (days) 79 54
Mortality rate 58 40
Overall readmission rate 23 16
o 28/30-day readmission rate 15 10
Economic Outcomes
Antimicrobial costs 91 62
Implementation costs 9 6
LOS costs 3 2
Operational costs 22 15
Cost savings 54 37
Othera 47 32
Abbreviations: LOS Length of stay
aOther outcome measures include but are not limited to mechanical ventilator
use, adherence to guidelines, QALYs, avoidable hospital cost, etc.
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implementation and operation of ASPs. Outcomes of inter-
est were separated into statistically significant results, non-
significant results or results of unknown significance. The
majority of the studies that measured significance reported
p-values with only one study reporting odds ratios [7]. Con-
fidence intervals were utilized in a few studies but also
alongside p-values. In this review, we therefore only exam-
ined significance based on studies reporting p-values. Stud-
ies that measured outcomes of interest and found that the
change in result values from pre- to post-intervention had
a p-value of < 0.05 were classified as statistically signifi-
cant. Studies with a change in result values that measured
a p-value of ≥0.05 were classified as non-statistically sig-
nificant. Studies that did not measure p-value were classi-
fied as no significance testing performed.
Results
The updated search from 2014 to 2017 identified a total of
487 potentially relevant citations, and of these, 411 ab-
stracts were excluded based on previously defined exclusion
criteria. A total of 76 papers were selected for full-review,
of which 44 studies met the inclusion criteria. Furthermore,
8 articles were included from supplemental searching. In
parallel to the updated search, the full-texts of all 99 studies
included in Dik et al. review were evaluated, of which 94
studies met our inclusion/exclusion criteria. As the primary
objective of the Dik et al. review was to evaluate only the
quality of these studies, we worked to synthesize the quan-
titative results of all these studies bringing the total count
to 146 primary research studies for final analysis from 2000
to 2017 (Fig. 1).
General characteristics
The majority of the studies analyzed were conducted in
North America (49%) and Europe (25%) with approxi-
mately two-thirds of the included articles being published
within the last 5 years. Most studies followed a quasi-ex-
perimental study design in medium-large hospitals with
500–1000 beds (Table 1). Most studies implemented an
“audit of and/or feedback on the antimicrobial therapy
provided” as an intervention strategy (57%), followed by
“altered therapy guidelines” i.e., creation of hospital treat-
ment guidelines specific to combating AMR or the alter-
ation of previous antimicrobial therapy guidelines (25%)
(Table 2). Even though we didn’t identify studies that ex-
clusively assessed behavioral change therapy, studies with
similar elements were included in “therapy feedback” and
“giving education”.
Outcomes from the interventions generally fell into
three categories: antibiotic use, patient outcomes, and
economic outcomes. The majority of the studies primar-
ily reported antibiotic outcomes, with 68% of studies
reporting changes in antibiotic usage. The most com-
monly reported patient outcomes were LOS and mortal-
ity within the hospital. For economic outcomes, 62%
reported changes in antibiotic expenditure and 37%
studies reported overall cost-savings (Table 2).
Antimicrobial outcomes
Antimicrobial usage
Of the 100 studies that reported antibiotic usage, 80
studies reported 108 relevant outcomes related to anti-
biotic usage [8–87]. Statistical significance testing was
performeded in 69% of these outcomes. Outcomes
measured included changes in drug dosage, including
defined daily dose (DDD), of certain antibiotics, changes
in duration of antimicrobial therapy, including days of
therapy (DOT), and proportion of patients on antimicro-
bial treatment. Most studies that measured antibiotic
usage were conducted in medium-large sized hospitals
with 500–1000 beds (26%).
Fig. 2 Effect of ASP on Total Antimicrobial Usage. SM = Significance measured; SNM = significance not measured. *Total usage of antibiotics
decreased in a majority of studies, as measured by drug dose, duration of therapy, proportion of patients receiving antibiotic therapy, or other outcomes
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Total usage of antibiotics decreased in majority of the
studies, as measured by drug dose, duration of therapy,
proportion of patients receiving antibiotic therapy, or
other outcomes (Fig. 2). Usage of individual antibiotic
classes (i.e., vancomycin, fluoroquinolones) demon-
strated mixed trends. In most studies, use of some anti-
microbials decreased, while use of other antimicrobials
increased or did not change.
Antimicrobial resistance
Eighteen of 22 studies measured relevant outcomes
related to AMR [7, 10, 11, 17, 19, 21, 23, 33, 34, 43,
63–65, 68, 82, 88–90]. Of these studies, 11 (61%)
found a statistically significant change in AMR follow-
ing implementation of a hospital ASP. These studies
measured resistance after a mean control period of
21.2 months (range: 6 months–36 months) and change
in resistance after a mean intervention period of 24.5
months (range: 6 months–36 months). Half the studies
demonstrated a decrease in resistance for at least one
microbial strain against an antimicrobial; two (11%)
studies demonstrated a decrease in resistance for at
least one antimicrobial coupled with an increase in resist-
ance towards a different antimicrobial. Such instances can
occur in an intervention strategy where the favored use
of a certain class of antibiotics may increase selection
pressure towards resistance. There was no obvious cor-
relation between primary intervention strategy utilized
and resistance, although the use of therapy evaluation,
review, and/or feedback was the strategy utilized in
both studies that reported both significant increases
and decreases in antimicrobial resistance between differ-
ent bacterial strains.
Patient outcomes
LOS
Of the 79 studies reporting LOS, 68 measured 93 pertin-
ent LOS outcomes [7, 8, 11, 17, 21, 24–26, 29, 31–33,
35–38, 40, 43–48, 50, 52, 56, 63, 66, 70, 72–79, 81–84,
89, 91–116]. Most of these studies occurred in medium-
large sized hospitals with 500–1000 beds (32%).
The majority of the 68 studies (85%) reported either a re-
duction or no change in LOS that ranged from a decrease
of 0 to 22 days (Table 3) after implementation of ASP. Only
10 studies reported an increase in LOS post-ASP imple-
mentation with a maximum increase of 5 days. More than
half of the 93 measured outcomes (53%) did not show a
statistically significant change; however, of the 33 outcomes
that did reach statistical significance, approximately 88%
showed a decrease in overall LOS. Studies of statistical sig-
nificance showed an average decrease in LOS of 3.24 days
or 20.6% per patient following ASP intervention.
Mortality rate
Most studies that evaluated mortality rate occurred in
medium-large sized hospitals with 500–1000 beds. Of 58
studies reporting mortality rate, 57 identified 73 relevant out-
comes related to mortality rate. Among those studies, 54
studies reported 58 all-cause mortality rate outcomes [7, 11,
15, 19–22, 27, 28, 31–33, 35, 38, 40, 44–48, 50–52, 59, 62,
70, 72, 73, 75–82, 85, 91, 92, 95, 96, 98, 99, 102, 104, 105,
109, 110, 112, 113, 116–119]. Additionally, only 11 of the 57
relevant studies reported 15 infection-related mortality out-
comes [7, 20, 48, 57, 74, 78, 79, 81, 83, 99, 109]. Statistical sig-
nificance testing was performeded in 91% of these outcomes.
Of the 54 studies that reported changes in all-cause
mortality, 77.2% reported reductions or no changes in
mortality ranging from 0 to 18.1% decrease (Table 3).
Similarly, the majority of the studies reporting infection-
related mortality also showed reductions or no changes
in mortality ranging from 0 to 12% decrease. Of the 58
all-cause mortality outcomes measured, 74% did not
reach statistical significance. Of the 10 measurements
that showed significance, 90% showed a decrease in
mortality rate. Among studies that reported significant
changes, there was an average decrease of 10.5% in all-
cause mortality rates and 11.3% decrease in infection-
related mortality rates following an ASP intervention.
Readmission rate
Twenty-three studies measured outcomes relevant to
hospital readmission rate. 21 studies measured 24 rele-
vant outcomes related to all-cause hospital readmission
rate [15, 22, 29, 35, 38, 44, 48, 50, 51, 70, 72, 77–79, 83,
95, 105, 108, 109, 111, 118] and 10 studies measured 12
outcomes related to infection relapse readmission [38,
48, 77–79, 82, 105, 109, 111, 113]. Most of these studies
occurred in medium-large sized hospitals with 500–1000
beds. Additionally, while there was variety in timepoint
chosen for measuring readmission rate amongst the stud-
ies (range: 48 h to 90 days), most studies measured re-
admission rate at 28 or 30 days [15, 22, 35, 44, 50, 51,
77–79, 82, 95, 109, 111, 113, 118].
Of the 21 studies that evaluated all-cause readmission
rates, 13 reported reduction or no changes ranging from
0 to 12%. Eight studies reported an increase in all-cause
readmission with a maximum increase of 8.6% (Table 3).
Of the 24 all-cause readmission outcomes, 86% did not
reach statistical significance. Outcomes of statistical sig-
nificance (n = 2) showed an average increase of 4.2% in
the all-cause readmission rate following ASP interven-
tion. Among the 12 infection-related readmission out-
comes, 33% reached statistical significance and all
showed a decrease in readmission rates (Table 3). Out-
comes of statistical significance (n = 4) showed an aver-
age decrease of 1.2% in the infection-related readmission
rate following ASP intervention.
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Economic outcomes
Implementation costs
Only 9 studies measured the cost of implementing an
ASP [9, 58, 68, 106, 114, 118, 120–122]. Overall imple-
mentation costs did not seem to be associated with the
type of ASP intervention (Table 3).
Operational costs
Operational costs were defined as the total direct hospital
costs associated with patient treatment for bacterial infec-
tion, typically including costs associated with LOS, diagnos-
tics, and treatment. A few studies also measured costs
associated with human resources. All included studies mea-
sured costs from the hospital perspective and reported ei-
ther total hospital costs or per patient costs both pre- and
post-intervention. Of 22 studies, 17 measured 20 relevant
operational cost outcomes, however only 13 studies includ-
ing 16 of those outcomes measured the change in oper-
ational costs from pre- to post-ASP intervention [7, 25, 56,
70, 86, 92, 93, 100–103, 112, 123]. Most of these studies
were from large hospitals with > 1000 beds (40%). Rapid
diagnostic tools were the most utilized intervention strategy.
Operational costs varied in if they increased or decreased
following ASP implementation, with 69% of outcomes dem-
onstrating a decrease in annual costs and 31% showing an
increase. Studies varied in reported currency so studies were
only averaged together based on currency type due to wide
discrepancies between currency conversion rates and years
that studies were conducted. Of the 12 USD ($) studies,
average ASP operational costs per patient were $5580 per
year and increased by 5.97% between pre- and post-
intervention, according to the 11 studies that measured
those changes. However, there was a wide range in this
change, with studies showing decreases in annual oper-
ational costs down to 72% or increases up to 236% (Table
3). Of the 4 EUR (€) studies, average ASP operational costs
per patient were €1974.47 per year. Similar trends of in-
creasing operational costs were exhibited amongst the 2 of 4
EUR (€) studies that measured change in cost with no stud-
ies exhibiting decreases in operational costs following ASP
implementation (range: 7.93 to 243%, Table 3).
Changes in operational costs seemed to have a correlation
with the intervention strategy utilized. Use of altered therapy
guidelines and antibiotic restriction lists of pre-authorized
agents typically reduced annual operational costs, on average
of 17.1 and 17.5%, respectfully. Therapy evaluation, review,
and/or feedback increased operational costs by an average
of 27.5%. Some interventions that utilized rapid diagnostic
testing or new biomarkers as their primary intervention
strategy more than tripled their operational costs at in-
creases of 236 and 243%, respectfully.
Antimicrobial expenditures
Of 91 studies, 87 measured 94 pertinent antimicrobial
expenditure outcomes but only 46% of outcomes were
assessed for statistical significance [8, 9, 12–22, 26, 28,
30–34, 37, 39–48, 52, 53, 55–58, 60, 62–68, 70–73, 75,
76, 82–84, 87–89, 91, 93, 95, 97, 99, 100, 104, 106, 107,
117, 118, 120, 122–138]. Most studies were conducted
in hospitals with 500–1000 patients (26%). Approxi-
mately 92% of the 87 studies showed a decrease in anti-
microbial costs ranging from 0.06 to 80.1%. Of the 94
Table 3 Literature synthesis of key outcomes: results and ranges
# Studies Reporting
Reductions or
No Change
Range # Studies Reporting
Increases
Range
Patient Outcomes
LOS 58 −21.9 to 0 days 10 0.1 to 5 days
All-cause mortality rate 41 −18.1 to 0% 13 0.02 to 11%
Infection-related mortality ratea 9 −12.0 to 0% 3 1 to 2.9%
All-cause readmission rate 13 −12 to 0% 8 0.2 to 8.6%
o 28/30-day 9 −10.86 to 0% 5 0.2 to 8.6%
Infection-related readmission rate 8 −2.94% to − 0.8% 2 0.3 to 0.65%
o 28/30-day 7 −2.94% to −0.7% 1 0.65%
Cost Outcomes
Implementation costs 0 N/A 9 $2.5 k to $39.9 k
Annual operational costsa 11 −72.4% to − 12.9% 5 7.9 to 243%
Antibiotic costs 80 −80.1% to − 0.06% 7 4.1 to 51.5%
LOS costsb 2 -$18.3 k to -$1.95 M 0 N/A
Overall hospital costsb 32 -$9.11 k to -$2.06 M 0 N/A
aIn these rows, the studies in the 2 columns are not mutually exclusive since more than 1 outcome was evaluated
bOnly included studies measuring cost outcomes in USDN/A = Not Applicable
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outcomes, only 15% did not reach statistical significance
compared to 31% that demonstrated significant change.
Of the outcomes that demonstrated significant changes,
97% showed a decrease in antimicrobial costs, averaging
35.6% decrease in costs following ASP implementation.
Only one study showed a significant increase of anti-
microbial costs (51.5%) (Table 3).
LOS costs
All 3 studies that reported changes in LOS costs demon-
strated decreases in costs following ASP implementation
[43, 66, 118]. This ranged from decreases of $18,305 for
a small hospital to $1.95M (Table 3) and 970,397 kr
(Swedish Krona/SEK) for two large sized hospitals. All
studies utilized therapy evaluation, review, and/or feed-
back as their primary intervention strategy.
Overall cost savings
Of 54 studies, 49 studies measured 58 relevant overall cost
savings outcomes [9–11, 23, 26, 27, 35, 36, 38, 42, 46, 49, 50,
52, 54, 57, 59, 60, 64, 76, 81, 82, 90, 91, 95, 96, 98, 99, 105,
106, 108, 112, 114, 117, 119, 120, 127–129, 134, 137, 139–
146]. Most of these studies were conducted in medium sized
hospitals with 150–500 beds (26%). Studies varied widely in
their reported currency as well as annual cost savings, al-
though most of the studies measured costs in US Dol-
lars (65%). Average cost savings in US Dollar (USD)
studies were $435,000 (range: $9110–$2.06 M) per year
for the hospital (Table 3), or $732 (range: $2.50 -$2640)
per patient. Average cost savings in Euro (EUR) studies
were €41,500 (range: €19,000–€66,200) per year for the
hospital, or €198.00 (range: €40.40–€529.00) per patient.
Average cost savings in Great Britain Pound (GBP) studies
were £144,000 (range: £7120–£286,000) per year for the
hospital, or £304.00 (range: £2.47–£1000) per patient.
Discussion
Through the implementation of a range of interventions,
hospital ASPs aim to provide high value for patients, with
value defined as the health outcomes achieved per dollar
spent [147]. This goal unites the interests of all the stake-
holders in the system, including patients. If value improves,
patients, payers, providers, and suppliers can all benefit
while the economic sustainability of the health care system
increases. This approach to considering sustainable funding
and prioritizing of ASP activity has been used successfully
in a range of other disease areas such as cardiovascular dis-
ease, diabetes, musculoskeletal diseases, etc. [148].
Value in health care is measured by the outcomes
achieved and not by the volume of services delivered
thereby shifting focus from volume to value. Value is also
not measured by the process of care used. Even though
process measurement and improvement are important
tactics they are not substitutes for measuring outcomes
and costs. Cost reduction without regard to the outcomes
achieved is dangerous and self-defeating, leading to false
“savings” and potentially limiting effective care.
Hospital ASPs aim to promote the efficient and judicious
use of antimicrobials to combat the rise in AMR. While
most ASPs focus on changes to antimicrobial use practices,
the effects of ASPs often yield downstream effects that ex-
tend from antimicrobial use into improved or maintained
patient outcomes (numerator of the value equation) which
drive down resource utilization and associated costs (de-
nominator of the value equation). To reduce cost, the best
approach is often to spend more on some services to
Fig. 3 Conceptual value framework for implementation
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reduce the need for others. Despite some significant limita-
tions [described later] of the available data, the majority of
the studies included here appear to produce similar results
in support of our value framework (Fig. 3), particularly in
relation to ASPs in North America and Europe. However,
there were a number of studies which reported contradic-
ting results, such as an increase in the use of certain antibi-
otics, worsening of some patient outcomes, and increased
hospital costs. It is important to try to understand potential
reasons for this.
In relation to antibiotic use, a few studies demon-
strated a significant increase in use of at least one anti-
biotic class [10, 31, 32, 72, 76]. This could be due to
many reasons including an inappropriate metric for
measuring antimicrobial use [76]. For example, an in-
crease in use of narrow spectrum antibiotic use offsets
a decrease in broad spectrum use yielding lower AMR
[10, 31, 32, 72]. Additionally, if the consumption of
only certain antibiotics is restricted, a global decrease in
resistance cannot be expected [63]. It is possible that re-
sistant strains are unrelated to changes made in hospitals,
as there may be an inability to differentiate between com-
munity- or hospital-acquired isolates [17, 21].
Some studies found that patient LOS increased follow-
ing ASP implementation [21, 36, 44–46, 70, 75, 82, 97,
102]. LOS can be influenced by factors beyond antibiotic
use, including comorbidities and disease severity, yielding
non-statistically significant increases in patient hospital
days [21, 36, 44, 75, 82, 97, 102]. Targeted interventions
(e.g., focus on reducing particular antibiotics) may not lead
to overall changes in LOS [36, 97, 102]. Short study dura-
tions or changes in pre- and post-intervention populations
may also compromise the direct results of the ASP on glo-
bal LOS [45, 46, 75, 82, 97, 102]. Similarly, a few studies
found that patient mortality increased following ASP im-
plementation but majority of these studies did not show
statistical significance [33, 45, 46, 70, 78, 79, 99, 102, 113].
Reasons could include short study durations [45, 82], pres-
ence of an existing ASP prior to the new intervention
strategy that may have limited the ASP impact [82], de-
layed therapy due to unavailable diagnostic results [102,
113], or poor communication between ASP staff members
regarding treatments [82, 113]. Differences in the pre- and
post-ASP populations and poor communication between
ASP staff members may be factors that led to an increase
in readmission rates in some studies [72, 77].
The small number of economic outcome studies that
do not show a significant reduction in antimicrobial
costs following an ASP instead showed no significant
changes or did not measure changes for significance [17,
28, 83, 97, 100]. Short study durations [97], increase in
the use of higher cost antibiotics that are more effective
in decreasing AMR [17, 41], and lack of adherence to
ASP interventions by all hospital staff members [41]
could lead to increase in antimicrobial costs.
Overall an increase in ASP costs may be offset by total
cost savings for the hospital [70, 112]. In addition, at a
per-patient level, the average per-patient cost savings
represents a significant portion of a hospital bed-day
cost. For example, in the EU and UK, the proportion of
a bed day saved through ASP represents 60–80% of the
cost of a bed day, while in the US the proportion of a
bed day saved is lower (~ 32%). Reduced patient LOS is
often the key driver of per patient cost savings for a hos-
pital and may explain the significant difference in cost
savings that were found between US, UK, and EU hospi-
tals. As per Table 4, average higher per patient cost sav-
ings were realized in studies conducted in the US, largely
due to the high cost of a hospital bed day in the country.
There were some limitations associated with the stud-
ies included in this review. First, there was heterogeneity
among the studies, in terms of size of hospitals and pa-
tient populations included in the review, as previously
described in Table 1. Some studies implemented ASPs
across the entire hospital with patient pools of nearly
13,000 [43], whereas other hospitals only implemented
their programs in specific wards or units with < 500 pa-
tients [75, 106]. Furthermore, numerous studies did not
indicate the size of their hospital bed size, patient popu-
lation, or both, making it challenging to compare their
results to either smaller medical centers with < 100 beds
[15] or large hospitals with > 600 beds [43]. The geo-
graphic distribution and provision of healthcare delivery
is biased towards the North American and European
hospital setting thereby rendering it difficult to apply
these findings globally. This challenge is further driven
by the wide range in years that the studies were con-
ducted as well as their reported currency, preventing a
comparison of the economic results on the same cur-
rency and same inflation rate. Homogenizing the cur-
rency and year of the studies would have allowed us to
conduct more analysis into the effectiveness of
Table 4 Cost savings compared with bed day costs around the world
United States European Union United Kingdom
Annual Per Patient Cost Savings with ASP $732.00 €198.00 £304.00
Average Hospital Bed Day Cost, 2015 $2271 [2] €328.64 [154, 155]a £375.86 [154, 155]a
Estimated Cost Offset as a Bed Day Saved Annually 32% 60% 80%
aOriginal WHO 2008 costs in I$ were inflated to 2015 costs and converted to Euro or Pound Sterling
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different ASP strategies and program designs to draw
conclusions on why certain programs drove improved
outcomes and cost savings. Additionally, the studies
varied in the type of ASPs, outcomes and follow-up
periods. Despite this limitation, our review was not re-
strictive in the studies included. Second, the majority
of the studies did not report start-up and implementa-
tion costs. The main economic outcome of interest
was costs associated with antimicrobial use. More
well-designed studies are needed that will evaluate the
costs of implementing ASPs to truly capture the eco-
nomic burden.
This is the first systematic review that provided a com-
prehensive summary of results of the economic impact
of ASPs. Given our objective to conduct a broad review
of the financial literature evaluating ASPs, the search
was not restricted to only include certain study designs,
interventions or study durations. A future step would be
to conduct a meta-analysis of the results with restrictive
inclusion/exclusion criteria to further delve into the rela-
tionships between specific ASP interventions and eco-
nomic outcomes.
Conclusions
Overall this systematic review demonstrates that ASPs
can offset or reduce costs while improving some patient
outcomes, thereby suggesting high value for certain
healthcare systems. The findings also suggest that costs
associated with start-up and implementation of ASPs
are potentially offset by subsequent cost-savings. Add-
itionally, numerous systematic reviews and meta-analyses
have demonstrated that such programs have beneficial ef-
fects on hospital LOS [149, 150], resistance patterns [63,
150], and infection incidence [151]. This data supports the
value of ASPs in tandem with infection control measures
[1]. However, for the findings to be globally relevant, more
studies, particularly in real world settings across a diverse
range of geographies and resource settings are required,
so that a full critical appraisal of the true value of these
programs can be made. This will not only allow our
ability to develop high value bespoke models of ASP
based on robust clinical and economic data but also
consider creating benchmarks, an area fraught with
challenges [152, 153].
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